One of the critically important features of successful treatment for functional gastrointestinal disorders, such as functional dyspepsia, is a sound patient-physician relationship. The physician ...

Dear Mayo Clinic: I have dealt with digestive issues for much of my 30s. Ulcers run in my family. My doctor said that while I could have an ulcer, testing could determine if it is functional dyspepsia ...

Functional dyspepsia is one of the most common gastrointestinal disorders encountered in clinical practice. Despite the frequency with which it occurs, this disorder remains poorly understood, and ...

Functional dyspepsia or nonulcer dyspepsia, and nonerosive reflux disease (NERD) or endoscopy-negative reflux disease, are common reasons for referral to a gastroenterologist. Although there is much ...

Please provide your email address to receive an email when new articles are posted on . CHARLOTTE, N.C. — Virtual reality significantly improved symptoms and quality of life in a small subset of ...

Currently, no FDA-approved drug therapies exist for pediatric patients with abdominal pain related to functional dyspepsia, a significant unmet medical need. In the absence of approved options, ...

Both hypnotherapy and medical treatment, in combination with psychological support, reduced symptoms of chronic nausea among pediatric patients with functional nausea and functional dyspepsia, ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Improvements in ...

CARMEL, Ind., Oct. 24, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing ...

Every day, in countless examination rooms around the world, patients are consulting their doctors about chronic stomach pain. In industrialized countries, medical evaluation usually uncovers no ...

A virtual reality headset using software consisting of passive and active immersive 3D audiovisual programs improved symptoms and quality of life for patients with functional dyspepsia, a randomized ...

CARMEL, Ind., May 20, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing ...